8i Acquisition 2 Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in Asia. The company was incorporated in 2021 and is based in Singapore.
IPO Year: 2021
Exchange: NASDAQ
Fastest customizable press release news feed in the world
Singapore, Nov. 23, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Ltd ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" (NASDAQ:EUDA) and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on N
Singapore, Nov. 17, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the "Business Combination") with EUDA Health Limited ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare. The combined company will operate under the name "EUDA Health Holdings Limited" and will be led by Founder and Chief Executive Officer Dr. Kelvin Chen. Commencing at the open of trading on November 18, 202
Singapore, Nov. 10, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (NASDAQ:LAX, the "Company"))), a special purpose acquisition company, announced today that all proposals presented to shareholders at the special meeting of shareholders held on November 10, 2022 at 10:00 a.m. Eastern Time relating to the Company's business combination with EUDA Health Limited were approved by shareholders. Holders of Company's ordinary shares that elected to redeem shares in connection with the Company's special meeting of shareholders may withdraw such redemption requests by no later than 5:00 p.m. Eastern Time on November 11, 2022. Based on a total of 8,195,770 ordinary shares tendered for redemption in
Singapore, June 10, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited ("EUDA Health"), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare, today announced an amendment to the Share Purchase Agreement (the "SPA Amendment") to, among other things, reduce the consideration payable by LAX to EUDA Health, and limit the earn-out payment available to the seller of EUDA Health in connection with the Share Purchase. As previously announce
Singapore, May 31, 2022 (GLOBE NEWSWIRE) -- 8i Acquisition 2 Corp. (the "Company" or "LAX") (NASDAQ:LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited, a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through personalized healthcare, today announced an amendment to the SPA (the "SPA Amendment") to extend the time for LAX to complete its financial, operational and legal due diligence review of EUDA Health from May 31, 2022 to June 15, 2022. As previously announced, LAX entered into a Share Purchase Agreement (the "SPA") dated April 11, 20
EUDA Health is disrupting the multi-trillion-dollar Southeast Asia healthcare industry with its proprietary unified AI platform that makes healthcare affordable, accessible, and personalized across Southeast Asia— one of the fastest growing healthcare technology markets in the world Pro forma enterprise value of the combined company is expected to be approximately $580 million with cash on hand of approximately $90 million, assuming no redemptions Singapore, April 12, 2022 (GLOBE NEWSWIRE) -- EUDA Health Limited, a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patient experience by delivering improved outcomes through pe
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
424B3 - EUDA Health Holdings Ltd (0001847846) (Filer)
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
EFFECT - EUDA Health Holdings Ltd (0001847846) (Filer)
F-1/A - EUDA Health Holdings Ltd (0001847846) (Filer)
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
F-1/A - EUDA Health Holdings Ltd (0001847846) (Filer)
6-K - EUDA Health Holdings Ltd (0001847846) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - EUDA Health Holdings Ltd (0001847846) (Issuer)
3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
4 - EUDA Health Holdings Ltd (0001847846) (Issuer)
3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
4 - EUDA Health Holdings Ltd (0001847846) (Issuer)
3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
4 - EUDA Health Holdings Ltd (0001847846) (Issuer)
3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
3 - EUDA Health Holdings Ltd (0001847846) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13D/A - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13G/A - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13D - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13D - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13G - EUDA Health Holdings Ltd (0001847846) (Subject)
SC 13G/A - 8i Acquisition 2 Corp. (0001847846) (Subject)
SC 13G - 8i Acquisition 2 Corp. (0001847846) (Subject)
SC 13G - 8i Acquisition 2 Corp. (0001847846) (Subject)